EUnetHTA 2019 Assembly & Forum Welcome Guide – Now Available
To accompany the upcoming EUnetHTA 2019 Assembly & Forum 0n 10-11th April in Amsterdam, a Welcome Guide has been developed to give participants and attendees a thorough overview of the event proceedings, practical information, and EUnetHTA’s working activities. The guide is created through the direct input of all EUnetHTA working groups and aims to […]
Declaration of Interest and Confidentiality Agreement (DOI) – Documents Now Available
EUnetHTA has developed documentation to address Conflict of Interest (COI) concerns and assist in the decision-making process relating to the assessment of individuals potentially involved in EUnetHTA JA3 activities. The Procedure Guidance for handling Declaration of Interest (DOI) details how to approach the step-by-step template form to generate a transparent assessment of stakeholder interests. Current […]
Open Call for Patient Input – Joint Assessment on a medicinal product for secondary progressive MS.
EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
2019 EUnetHTA Forum Agenda – Now Available
The day’s agenda is now available for the upcoming 2019 EUnetHTA Forum on 11th April at the West-Indisch Huis in central Amsterdam. We are looking forward to hosting a collaborative, informative session of talks that both outline progress made in European HTA, while scoping out expectations for the future. See the agenda HERE.
EUnetHTA Magazine: Winter 2019
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
PTJA04 – “Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.’ Below is the documentation provided […]
EUnetHTA 2019 Forum
Registration has now closed for the EUnetHTA 2019 Forum, held this year at the West-Indisch Huis in Amsterdam, the Netherlands, on 11 April 2019. Consisting of EUnetHTA Consortium partners, stakeholder groups, and other organisations involved in the activities of EUnetHTA JA3, the Forum provides a focal point for the open exchange of ideas and experience […]
The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available.
The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available. We are pleased to announce that the collaborative rapid assessment on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute […]
OTCA16 Bioresorbable Stents for the Treatment of Cardiovascular Indications (coronary artery disease) Final Assessment Now Available.
We are pleased to announce that the collaborative rapid assessment, OTCA16, on “BIORESORBABLE STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS (CORONARY ARTERY DISEASE)” is now available. The health technology assessed is a device for percutaneous coronary intervention (PCI). The objective of this assessment was to evaluate the relative effectiveness and safety of this technology in […]
Final assessment report on MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer
Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint® This is the assessment of the relative effectiveness of MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer Notice In the MammaPrint report the authors reported the number of events and […]
